Trimetazidine capsules 20mg №60

The drug is taken orally during meals.

The recommended dosage regimen is 2-3 capsules (40-60 mg) / in 2-3 doses. The doctor sets the course of treatment individually.

Indications and usage

- IHD: prevention of strokes (in combination therapy);

- chorioretinal vascular disorders;

- dizziness of vascular origin;

- Cochleo-vestibular disorders of the ischemic nature (tinnitus, hearing loss).

Contraindications

- renal failure (CC less than 15 ml / min);

- severe liver dysfunction;

- pregnancy;

- lactation period (breastfeeding);

- age up to 18 years (efficiency and safety have not been established);

- hypersensitivity to the drug.

Pharmacological properties

Antihypoxic and antianginal drug. Directly affecting the cardiomyocytes and neurons of the brain, optimizes their metabolism and function. The cytoprotective effect is due to increased energy potential, activation of oxidative decarboxylation and rationalization of oxygen consumption (increased aerobic glycolysis and blockade of fatty acid oxidation). Supports myocardial contractility, prevents a decrease in the intracellular content of ATP and phosphocreatine.Under conditions of acidosis, it normalizes the functioning of membrane ion channels, prevents the accumulation of Calcium and sodium in cardiomyocytes, and normalizes the intracellular content of potassium ions. Reduces intracellular acidosis and phosphate content due to myocardial ischemia and reperfusion. Interferes with the damaging effects of free radicals, preserves the integrity of cell membranes, prevents activation of neutrophils in the ischemic area, increases the duration of electrical potential, reduces the release of CPK from cells and the severity of ischemic myocardial damage.

When angina reduces the frequency of attacks (reduced consumption of nitrates), after 2 weeks of treatment increases exercise tolerance, reduced blood pressure drops.

Hearing and results of vestibular samples in patients are improved, dizziness and tinnitus are reduced.

When vascular pathology of the eye restores the functional activity of the retina.

Pharmacokinetics

Suction

After taking the drug inside Trimetazidine quickly and almost completely absorbed from the gastrointestinal tract. Bioavailability - 90%. The time to reach Cmax in the blood plasma is 2 hours. After a single dose of Trimetazidine at a dose of 20 mg, Cmax is about 55 ng / ml.

Distribution

Binding to plasma proteins - 16%.

Easily penetrates histohematogenous barriers.

Removal

T1 / 2 is 4.5-5 hours. Excreted by the kidneys, about 60% - unchanged.

Pregnancy and lactation period

The drug is contraindicated in pregnancy and lactation (breastfeeding).

Side effects

Allergic reactions:pruritus

Gastrointestinal: rarely - gastralgia, nausea, vomiting.

From the side of the central nervous system:rarely a headache.

Cardiovascular: feeling of heartbeat.

Overdosage

Currently, no cases of overdose have been reported.

Interaction with other drugs

Data on drug drug interactionsTrimectal® missing.

Special notes

On the background of drug treatment in patients with coronary artery disease there is a significant decrease in the daily need for nitrates.

Influence on ability to drive motor transport and control mechanisms

The drug does not affect the ability to drive vehicles and perform work that require high-speed psychomotor reactions.

Storage conditions

List B. The drug should be kept out of the reach of children, dry, protected from light, at a temperature not exceeding 25 ° C. Shelf life- 2 years.